TOKYO -- Daiichi Sankyo plans to begin Phase 3 clinical trials for its coronavirus vaccine this autumn with the aim of bringing it to the public in 2022, finally pushing forward Japan's effort to locally develop COVID-19 shots.
Coronavirus
Japan nears homegrown vaccine with Daiichi Sankyo Phase 3 trials
Shionogi eyes enough COVID shots for 60m people a year
